AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05019924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Semaine
Description: The dietary supplement is designed, and marketed commercially to be taken in servings of two capsules per day, up to four times per day (a total of 8 capsules daily). Most consumers, however, will only take a serving three times per day, or one with each major meal (breakfast, lunch and dinner).
Study NCT05077293 — intervention group
Intervention type: OTHER
Intervention: Best Practice Alert (BPA)
Description: A BPA will fire in the EHR reminding care providers of the best practice when prescribing medical therapies for heart failure patients.
Study NCT05077293 — intervention group
Intervention type: OTHER
Intervention: In-Basket Message
Description: An In-Basket message will be sent biweekly to care providers with a reminder of the best practice when prescribing medical therapies for heart failure
Study NCT06122090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Description: Bimatoprost will be delivered with laser
Study NCT06351722 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Before non-surgical periodontal treatment
Description: Clinical Measurements and Laboratory Measurement Saliva and serum samples will be collected from all patients initially. Clinical parameters will also be recorded initially. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist (ZTE) will record all clinical parameters using manual probing.~Following sampling, both serum and saliva samples will be stored at -80°C until analysis. Concentrations of NLRP3, ASC, caspase-1, IL-18, IL-1beta, TNF-alfa, IL-10, TGF-beta, and SIRT-1 will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in both serum and saliva samples. LncRNA SNHG5 and MEG3 will be examined using Real-time PCR.
Study NCT06122090 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline control will be delivered with laser
Study NCT04703959 — intervention group
Intervention type: OTHER
Intervention: polysomnography
Description: polysomnography is already done for all patients
Study NCT06351722 — intervention group
Intervention type: PROCEDURE
Intervention: non-surgical periodontal treatment
Description: Treatment will be performed using ultrasonic devices followed by root planing with gracey curettes. SRP will be completed in two visits, each consisting of quadrants every 2 days. Oral hygiene instructions will include demonstrating proper brushing techniques and the use of interdental cleaning aids as needed. Saliva and serum samples will be collected again at the 3-month follow-up visit, all clinical parameter records will be repeated by the same clinician (ZTE), and oral hygiene instructions will be reconfirmed as needed. After the collection of 3-month records and samples, all patients with persistent pockets will be subjected to a standard periodontitis treatment protocol.
Study NCT06351722 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3rd month after non-surgical periodontal treatment
Description: All clinical and laboratory evaluations described under the heading Before non-surgical periodontal treatment will be repeated in the 3rd month after NSPT.
Study NCT06120439 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PECS II combined with intercostal nerve blockade;
Description: The patient was in a supine position, and under ultrasound guidance, the needle tip was first placed in the plane between the pectoralis major and minor muscles, and 10ml of 0.3% ropivacaine was injected. The needle was then advanced into the space between the pectoralis minor and serratus anterior muscles, and 20ml of 0.3% ropivacaine was injected. Intercostal nerve blockade: The range of intercostal blockade was determined based on the location of the breast surgery. The needle was inserted into the intercostal space from the posterior axillary line, and 3ml of 0.3% ropivacaine was injected into each intercostal space.
Study NCT06120439 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with laryngeal mask
Description: The C Group underwent general anesthesia induction using TCI propofol 3-3.5μg/ml, TCI remifentanil 1-2ng/ml, sufentanil 0.3μg/kg iv, midazolam 0.05mg/kg iv, and rocuronium 0.6mg/kg iv after loss of consciousness. After muscle relaxation, the laryngeal mask was inserted, and mechanical ventilation was performed with a tidal volume of 6ml/kg. Anesthesia maintenance included propofol 3-4μg/ml and remifentanil 1-2ng/ml.
Study NCT06076863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Care
Description: Management of Paxlovid e-visits per regional protocol
Study NCT01311193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light therapy
Description: early morning exposures to bright light, 8000lux for 40min, daily during 3 weeks
Study NCT05957783 — intervention group
Intervention type: OTHER
Intervention: Cerebral palsy Gait analysis technique
Description: Visual gait analysis in cerebral palsy new technique
Study NCT06076863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AFM Pool Care
Description: Management of Paxlovid e-visits per regional and local protocols
Study NCT04328974 — intervention group
Intervention type: PROCEDURE
Intervention: lumbar CSF drainage
Description: We have performed the lumbar CSF drainage on the level of the lumbar spine between L3 and L4 with the patient lying in the lateral decubitus position with hips and knees flexed. A lumbar drainage catheter was inserted using a HermeticTM lumbar accessory kit (Integra Neurosciences, Plainsboro, NJ, USA) in the patients. ICP monitoring via lumbar drainage catheter was practiced using the LiquoGuard® (Möller Medical GmbH \& Co KG, Fulda, Germany). ICP control strategies was initiated when ICP exceeded 15 mmHg in the absence of noxious stimuli at the rate of 10\~20 ml/h via a lumbar drainage catheter until ICP was less than 15 mmHg \[14, 15\].
Study NCT05398939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test and skin evaluation
Description: The patients received blood tests for serum 25-hydroxyvitamin D level and skin evaluation for severity of acne vulgaris and lesion counts.
Study NCT06541184 — intervention group
Intervention type: DRUG
Intervention: Ziconotide [Prialt]
Description: Intrathecal injection of ziconotide, using an internal pump, surgically inserted by a trained neurosurgeon or anesthesiologist, under general anesthesia.
Study NCT05786417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Discretion
Description: Clinician discretion as to which BB or CCB will be used if the participant has a heart rate and blood pressure within normal limits.
Study NCT06539117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early feeding post caesarean section
Description: In this group, participants were encouraged to commence oral sips of 150 millilitres of water from 6 hours post-caesarean delivery by the staff nurse. Thereafter, they were given semi-solid diet (250 milliliter of pap) from the 12th hour, and subsequently solid diet (a plate of well- cooked rice) by the trained nursing staff.
Study NCT06539117 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early feeding post caesarean section
Description: In this group, participants were encouraged to commence oral sips of 150 millilitres of water from 6 hours post-caesarean delivery by the staff nurse. Thereafter, they were given semi-solid diet (250 milliliter of pap) from the 12th hour, and subsequently solid diet (a plate of well- cooked rice) by the trained nursing staff.
Study NCT06182644 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FAPI PET/CT
Description: The same group of patients underwent FAPI PET/CT and FDG PET/CT examinations respectively
Study NCT05786417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Selection of the specific BB and initial starting dose will be determined by the treating clinician.
Study NCT05786417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker
Description: Selection of the specific CCB and initial starting dose will be determined by the treating clinician.
Study NCT05781711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa-carbidopa
Description: levodopa-carbidopa is the standard therapy used in Parkinson's disease
Study NCT05781711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa-carbidopa
Description: levodopa-carbidopa is the standard therapy used in Parkinson's disease
Study NCT05781711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin, a biguanide family member commonly used in treatment for type 2 diabetes, appears to increase liver and peripheral tissue sensitivity to insulin as well as reduce hepatic glucose production
Study NCT05405985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Nemolizumab with Auto-Injector (AI).
Study NCT05405985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Nemolizumab with Dual-Chamber Syringe (DCS).
Study NCT05808764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Participants will receive 0.15 mg/kg risdiplam orally once daily for 28 days.
Study NCT04799197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kicking it with the Gurlz
Description: The intervention is a multicomponent intervention, including a screening, groups, and individual sessions.
Study NCT04793334 — intervention group
Intervention type: PROCEDURE
Intervention: sleeve gastectomy
Description: routine sleeve gastrectomy
Study NCT06524323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil Injection
Description: The mixture contains 2mL of triamcinolone acetonide injection and 4mL of 5-fluorouracil injection, which is diluted with saline to 10mL.
Study NCT06524323 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone Acetonide
Description: The mixture contains 2mL of triamcinolone acetonide injection which is diluted with saline to 10mL.
Study NCT05188131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion of Diclofenac Sodium
Description: Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.
Study NCT05188131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Infusion of Placebo
Description: Intravenous Infusion of Placebo (represented by 100 ml of isotonic saline) is administered over 15 minutes.
Study NCT05033639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 6 MG
Description: Melatonin is an endogenously produced indolamine principally synthesized in the pineal gland from serotonin. It is described as a ubiquitous molecule which plays a vital role in the physiologic function of the body. Melatonin, also known as N-acetyl-5-methoxytryptamine which has a a) immunomodulator; b) free radical scavenger; c) prevention of oxidative stress and d) anti-inflammatory7-10.
Study NCT05033639 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Breast Milk
Description: Naturally occurring milk from the mother of the infant.
Study NCT05552352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality assisted information
Description: Patients in the intervention group receive a VR instructional application in the patient's room the day before TAVI implantation and in the operational suite during TAVI implantation the next day. In this application, the patient is guided through different VR parts that repeat the indication, the procedure, the localities and the post-interventional phase of the implantation with the corresponding safety instructions.
Study NCT05391256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated flying Drone carrying an Automated external defibrillator (AED)
Description: Totally n=6 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over up to 12 months Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.~An interventional package directed to the dispatchers is distributed and consists of an e-learning program, an AED -trainer placed at the dispatch center. Within the dispatcher decision tool - there is information how to inform the caller to retrieve the AED. The HEMS-coordinator reminds the dispatcher during the call on operational information. Monthly information to staff of project progress is provided.
Study NCT05244551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK061
Description: In the escalation part, patients will receive a single dose of oral ABSK061 on C1D1 only, and then BID dosing for the rest of the days of cycle 1 and in subsequent cycles (28-day cycles). The starting dose is 5 mg BID. In the expansion part, patients will each receive oral ABSK061 at the RDE in repeated 28-day cycles.
Study NCT04692532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-hour Time restricted eating
Description: Ad libitum food intake from 12-8 pm every day Fasting from 8-12 pm every day (16-h fast)
Study NCT04692532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Description: 25% energy restriction every day
Study NCT01086943 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LT2420
Study NCT04938011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: progesterone
Description: the transfer of day 6 blastocyst on the 6th day of progesterone supplementation
Study NCT04938011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone
Description: the transfer of day 6 blastocyst on the 7th day of progesterone supplementation
Study NCT06506409 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart-Video Based Game Therapy
Description: The Active Arcade program will be practiced 2 days a week for 8 weeks. Individuals in this group will be given a 1-minute rest break between games. Sessions will be approximately 30 minutes. Selected games focus on balance, coordination and weight transfer.
Study NCT06506409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Otago Based Structured Exercise
Description: Exercises will be done 2 days a week for 8 weeks and last approximately 30 minutes. In general, if individuals can perform 2 sets of 10 repetitions at a difficulty level with quality, they can move on to a higher difficulty level. It consists of warm-up, balance and strengthening exercises. It was developed to increase balance.
Study NCT06506409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: A training presentation based on the guidelines and individuals' needs will be developed for participants in the control group. The presentation will include an infographic developed with the CANVA program, a test created with Google Forms, and a summary video developed with the Powtoon program. The created presentation will be presented online to individuals in the control group, and the participants will be followed by phone once a week for 8 weeks. The topics of the training will be: What is Osteoporosis, Osteoporosis Prevalence, Findings and Risk Factors, Diagnosis of Osteoporosis, Osteoporosis Prevention and Nutrition, Osteoporosis and Exercise, Preventing Falls.
Study NCT05540834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: The enzyme tissue plasminogen activator that cleaves plasminogen to form plasmin.
Study NCT01261182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In School Feeding
Description: The intervention provides meals consisting of 1049 kcals of energy, 32.6 gm protein, and 24.9 gm fat per child per school day and meet at least two thirds of the child's daily vitamin and mineral requirements, including 99 percent of iron requirements. SFP delivers these nutrients in the form of a fortified corn-soy porridge around mid-morning and beans and maize meal or rice at lunch.
Study NCT04959305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1803-3
Description: Take it once daily for 8 weeks orally.
Study NCT04959305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2003
Description: Take it once daily for 8 weeks orally.
Study NCT04959305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2004
Description: Take it once daily for 8 weeks orally.
Study NCT04959305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RLD2005
Description: Take it once daily for 8 weeks orally.
Study NCT04959305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPP2003-3
Description: Placebo drug. Take it once daily for 8 weeks orally.
Study NCT04959305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP2005
Description: Placebo drug. Take it once daily for 8 weeks orally.
Study NCT05360745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ARACOMPLEX®
Description: ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.
Study NCT05360745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
Study NCT05825560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OFA multimodal analgesia
Description: Multimodal opioid free analgesia
Study NCT05825560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard multimodal analgesia
Description: Standard remifentanil analgesia
Study NCT05694299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal bridle
Description: Bridle Pro® Nasal Tube Retaining System (Applied Medical Technology Inc., Brecksville, OH, USA)
Study NCT05694299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal patch
Description: Regular adhesive tape for medical use.
Study NCT05597553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Premixed MTA
Description: The premixed Bio-ceramic putty during setting become hard and expand slightly providing a superior long-term seal
Study NCT05597553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Premixed MTA
Description: The premixed Bio-ceramic putty during setting become hard and expand slightly providing a superior long-term seal
Study NCT05597553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Powder/liquid MTA
Description: Mineral trioxide aggregate (MTA) is a silicate material that is said to aid in faster bridge formation with fewer tunnel defects, less pulpal inflammation, and the maintenance of pulpal integrity. It is widely used in pediatric dentistry due to its excellent sealing properties.
Study NCT05597553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powder/liquid MTA
Description: Mineral trioxide aggregate (MTA) is a silicate material that is said to aid in faster bridge formation with fewer tunnel defects, less pulpal inflammation, and the maintenance of pulpal integrity. It is widely used in pediatric dentistry due to its excellent sealing properties.
Study NCT01261182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Take Home Rations
Description: The rations provided in the intervention are equal in size and composition to the food received in the in-school feeding intervention, but are provided to households once per month.
Study NCT05905731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-T
Description: Stage-1: Patients will receive three biweekly HBV-TCR T cell infusions at escalating doses, ranging from 1 x 10\^5 cells/kg to 5 x 10\^6 cells/kg bodyweight (by IV infusion). Patients are to remain on existing HBV NUC treatment.~Stage-2: Patients will receive three biweekly HBV-TCR T cell infusions at maximum dose as determined in Stage-1 study. Patients are to remain on existing HBV NUC treatment.
Study NCT05350319 — intervention group
Intervention type: RADIATION
Intervention: A low-dose CT scan of the shoulder
Description: Briefly, a conventional CT scan will be conducted, with scan images representing a reconstruction of simultaneous scans at two sensors. L-CT images will be derived from single source data (ie the scan data gathered by one of the emitters rather than a reconstruction from both).
Study NCT04707885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocochleography
Description: The use of ECochG monitoring will be employed. This will be conducted intraoperatively during the entire portion of the CI electrode insertion component.~For the purposes of this clinical trial, the stimulus will consist of a 500 Hz tone burst presented at \~105-110 dB SPL. This was chosen due to the time and resource limitations in the operating room. Hence, the surgical team can only utilize a very limited dataset for intraoperative decision making and previous studies have demonstrated that 500 Hz stimulation offers the most robust, reliable, and useful ECochG signal during electrode insertions.
Study NCT05510674 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OWL-EVO1
Description: EVOC probe
Study NCT04685525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mycobiome Supporting Diet
Description: MSD takes combines elements from several diets (e.g., Paleo, low-carbohydrate, vegetarian, and Mediterranean) and excludes elements of these diets that have been specifically proven to increase pathogenic fungi in the human gut.
Study NCT05192655 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation Study